Mitsubishi Tanabe Pharma Korea said that it would import and market Zolpimist, an insomnia treatment, in Korea.
Suda, a pharmaceutical company based in Australia, is the manufacturer of Zolpimist.
Zolpimist is a spray-type fast-acting insomnia treatment approved by the U.S. Food and Drug Administration in 2008. The drug demonstrated its bioequivalence to the original product Stilnox (Ingredient: Zolpidem) in clinical trials.
The drug has optimized the solubility, safety, and permeability of oral spray formulations by introducing Oromist technology, which allows patients to absorb the medicine directly into the bloodstream through the oral mucosa, according to Mitsubishi Tanabe Pharma Korea.
As patients can absorb the drug faster than an oral formulation of zolpidem, it shows a more rapid effect. It also reduces the time for insomnia patients to fall asleep, which, in turn, can help patients with delirium symptoms. As it is absorbed through the oral mucosa, it is also convenient for patients who have difficulty swallowing pills as there is no need to take extra water.
“We are delighted to be able to supply a more convenient and quick-acting oral spray formulation of insomnia treatment to local insomnia patients through the agreement with Suda,” Mitsubishi Tanabe Pharma Korea President Narihiko Yoshii said.
The company will continue to provide new products and high-quality medical information necessary for the medical field to become a global pharmaceutical company that strives for the development of the medical field, he added.
<© Korea Biomedical Review, All rights reserved.>